DUBLIN–(BUSINESS WIRE)–The “Generalized Anxiety Disorder (GAD) – Market Insights, Epidemiology, and Market Forecast – 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Generalized Anxiety Disorder (GAD)- Market Insights, Epidemiology, and Market Forecast-2028′ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Generalized Anxiety Disorder in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Generalized Anxiety Disorder from 2017 to 2028 segmented by seven major markets.

Generalized Anxiety Disorder Generalized anxiety disorder (GAD) is characterized by persistent, excessive, and unrealistic worry about everyday things. This worry could be multi focal, such as finance, family, health, and the future. It is in excess, is difficult to control, and often accompanied by many non-specific psychological and physical symptoms. Excessive worry is the central feature of GAD.

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria is the updated criteria for GAD that separated out different mental disorders as anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, and other conditions caused by anxiety disorders.

Generalized Anxiety Disorder – Disease Understanding and Treatment Algorithm

The criteria of GAD in DSM-V include the characteristics, such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months with at least three of the core symptoms in adults and one sign in the case of children.

Although the precise cause of GAD is unknown, scientific studies show that a combination of biological, genetic, cognitive, and environmental factors also play a role in GAD.

Generalized Anxiety Disorder Epidemiology

(Read more…)

The Generalized Anxiety Disorder epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

According to this research, the total prevalent cases of Generalized Anxiety Disorder in the 7MM was found to be 16,606,987 in 2017. The prevalence of Generalized Anxiety Disorder in the 7MM is expected to increase during the study period of 2017-2028.

Generalized Anxiety Disorder Drug Chapters

This segment of the Generalized Anxiety Disorder report encloses the detailed analysis of and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Various types of therapies can help with GAD, such as supportive and interpersonal therapy. Cognitive-behavioral therapy (CBT) has been more researched and specifically targets thoughts, physical symptoms, and behaviours, including the over-preparation, planning, and avoidance that characterizes GAD, along with this pharmacotherapy is also used.

The current market of Generalized Anxiety Disorder is centered on the destruction of lesions by psychological interventions, pharmacological interventions, or a combination of these modalities.

The standard category of pharmacological agents used in the management of GAD includes Selective serotonin re-uptake inhibitors (SSRIs), Selective norepinephrine reuptake inhibitors (SNRIs), Pregabalin, Tricyclic antidepressants (TCAs), Benzodiazepines, Antihistamines, Atypical antipsychotics, Antioxidants, and others.

Among the pharmacological therapies, SSRIs (Paroxetine, Escitalopram, Sertraline, Fluoxetine, and others) are commonly used treatment as the first line of therapy. They can relieve anxiety symptoms and help to reduce the symptoms of depression that often accompany anxiety disorders.

Companies are working on therapies, such as Troriluzole (BioHaven), Escitalopram (Allergan) and others. These are anticipated to enter the Generalized Anxiety Disorder market by 2028.

Generalized Anxiety Disorder Market Outlook

The Generalized Anxiety Disorder market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to this research, the market of Generalized Anxiety Disorder in 7MM was found to be approximately USD 1,916.98 Million in 2017.

Generalized Anxiety Disorder market size in the United States accounted for approx. 67% of the total market in 2017. The US-led the market in 2017, followed by the EU5 and Japan respectively. Due to the high prevalence of this disease in the region, the Generalized Anxiety Disorder treatment market in the US is expected to dominate the market during the forecast period (2019-2028).

Generalized Anxiety Disorder Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Currently, the market of Generalized Anxiety Disorder depends on SSRIs, SNRIs as the first choice of therapy. However, in cases when SSRIs and SNRIs are ineffective or in severe cases, Benzodiazepines, Tricyclic Antidepressants, Azapirone (Buspirone) are the choice of treatment. Along with this other modality such as Antiepileptics, antipsychotics, etc. are also recommended.

The therapies in the late stage of development are Troriluzole (BioHaven), Escitalopram (Allergan) for patients with Generalized Anxiety Disorder.

Generalized Anxiety Disorder Report Insights

• Patient Population of Generalized Anxiety Disorder
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Generalized Anxiety Disorder Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Generalized Anxiety Disorder Report Assessment

• Current Treatment Practices
• Unmet Needs
• Case Report
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving Generalized Anxiety Disorder market
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder market
• To understand the future market competition in the Generalized Anxiety Disorder market

Key Topics Covered:

1. Key Insights

2. Generalized Anxiety Disorder (GAD): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of GAD in 2017

2.2. Total Market Share (%) Distribution of GAD in 2028

3. Key Summary

4. Epidemiology and Market Methodology

5. Disease Background and Overview: Generalized Anxiety Disorder (GAD)

5.1. Introduction

5.2. Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Epidemiology and Patient Population: Generalized Anxiety Disorder

6.1. Key Findings

6.2. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM

6.3. The United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. The United Kingdom (UK)

6.10. Japan

7. Current Treatment

7.1. Treatment of special populations

7.2. Treatment Guidelines

8. Unmet Need

9. Case Report

9.1. A Case Report of GAD and Changes in Treatment Plan Based on Patient Care Scenario: Follow up

10. Marketed Drugs

10.1. Key Cross Competition- Key therapies

11. Emerging Drugs

11.1. Key Cross Competition

11.2. Key Cross Competition- Potential therapies

11.3. Troriluzole: BioHaven Pharmaceuticals

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. Escitalopram: Allergan

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Safety and Efficacy

11.4.5. Product Profile

12. Market Size: Generalized Anxiety Disorder

12.1. Key Findings

12.2. Total Market Size of Generalized Anxiety Disorder in 7MM

12.3. Total Market Size of Generalized Anxiety Disorder by Therapies in 7MM

13. Market Outlook: 7 MM

14. Market Drivers

15. Market Barriers

16. Bibliography

17. Appendix

17.1. Report Methodology

18. Researcher Capabilities

19. Disclaimer

20. About the Publisher

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Generalized Anxiety Disorder (GAD) – Market Insights, Epidemiology, and Market Forecast – 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Generalized Anxiety Disorder (GAD)- Market Insights, Epidemiology, and Market Forecast-2028′ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Generalized Anxiety Disorder in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Generalized Anxiety Disorder from 2017 to 2028 segmented by seven major markets.

Generalized Anxiety Disorder Generalized anxiety disorder (GAD) is characterized by persistent, excessive, and unrealistic worry about everyday things. This worry could be multi focal, such as finance, family, health, and the future. It is in excess, is difficult to control, and often accompanied by many non-specific psychological and physical symptoms. Excessive worry is the central feature of GAD.

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria is the updated criteria for GAD that separated out different mental disorders as anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, and other conditions caused by anxiety disorders.

Generalized Anxiety Disorder – Disease Understanding and Treatment Algorithm

The criteria of GAD in DSM-V include the characteristics, such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months with at least three of the core symptoms in adults and one sign in the case of children.

Although the precise cause of GAD is unknown, scientific studies show that a combination of biological, genetic, cognitive, and environmental factors also play a role in GAD.

Generalized Anxiety Disorder Epidemiology

(Read more…)

The Generalized Anxiety Disorder epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

According to this research, the total prevalent cases of Generalized Anxiety Disorder in the 7MM was found to be 16,606,987 in 2017. The prevalence of Generalized Anxiety Disorder in the 7MM is expected to increase during the study period of 2017-2028.

Generalized Anxiety Disorder Drug Chapters

This segment of the Generalized Anxiety Disorder report encloses the detailed analysis of and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Various types of therapies can help with GAD, such as supportive and interpersonal therapy. Cognitive-behavioral therapy (CBT) has been more researched and specifically targets thoughts, physical symptoms, and behaviours, including the over-preparation, planning, and avoidance that characterizes GAD, along with this pharmacotherapy is also used.

The current market of Generalized Anxiety Disorder is centered on the destruction of lesions by psychological interventions, pharmacological interventions, or a combination of these modalities.

The standard category of pharmacological agents used in the management of GAD includes Selective serotonin re-uptake inhibitors (SSRIs), Selective norepinephrine reuptake inhibitors (SNRIs), Pregabalin, Tricyclic antidepressants (TCAs), Benzodiazepines, Antihistamines, Atypical antipsychotics, Antioxidants, and others.

Among the pharmacological therapies, SSRIs (Paroxetine, Escitalopram, Sertraline, Fluoxetine, and others) are commonly used treatment as the first line of therapy. They can relieve anxiety symptoms and help to reduce the symptoms of depression that often accompany anxiety disorders.

Companies are working on therapies, such as Troriluzole (BioHaven), Escitalopram (Allergan) and others. These are anticipated to enter the Generalized Anxiety Disorder market by 2028.

Generalized Anxiety Disorder Market Outlook

The Generalized Anxiety Disorder market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to this research, the market of Generalized Anxiety Disorder in 7MM was found to be approximately USD 1,916.98 Million in 2017.

Generalized Anxiety Disorder market size in the United States accounted for approx. 67% of the total market in 2017. The US-led the market in 2017, followed by the EU5 and Japan respectively. Due to the high prevalence of this disease in the region, the Generalized Anxiety Disorder treatment market in the US is expected to dominate the market during the forecast period (2019-2028).

Generalized Anxiety Disorder Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Currently, the market of Generalized Anxiety Disorder depends on SSRIs, SNRIs as the first choice of therapy. However, in cases when SSRIs and SNRIs are ineffective or in severe cases, Benzodiazepines, Tricyclic Antidepressants, Azapirone (Buspirone) are the choice of treatment. Along with this other modality such as Antiepileptics, antipsychotics, etc. are also recommended.

The therapies in the late stage of development are Troriluzole (BioHaven), Escitalopram (Allergan) for patients with Generalized Anxiety Disorder.

Generalized Anxiety Disorder Report Insights

• Patient Population of Generalized Anxiety Disorder
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Generalized Anxiety Disorder Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Generalized Anxiety Disorder Report Assessment

• Current Treatment Practices
• Unmet Needs
• Case Report
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This report will help to develop Business Strategies by understanding the trends shaping and driving Generalized Anxiety Disorder market
• Organize sales and marketing efforts by identifying the best opportunities for Generalized Anxiety Disorder market
• To understand the future market competition in the Generalized Anxiety Disorder market

Key Topics Covered:

1. Key Insights

2. Generalized Anxiety Disorder (GAD): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of GAD in 2017

2.2. Total Market Share (%) Distribution of GAD in 2028

3. Key Summary

4. Epidemiology and Market Methodology

5. Disease Background and Overview: Generalized Anxiety Disorder (GAD)

5.1. Introduction

5.2. Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Epidemiology and Patient Population: Generalized Anxiety Disorder

6.1. Key Findings

6.2. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM

6.3. The United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. The United Kingdom (UK)

6.10. Japan

7. Current Treatment

7.1. Treatment of special populations

7.2. Treatment Guidelines

8. Unmet Need

9. Case Report

9.1. A Case Report of GAD and Changes in Treatment Plan Based on Patient Care Scenario: Follow up

10. Marketed Drugs

10.1. Key Cross Competition- Key therapies

11. Emerging Drugs

11.1. Key Cross Competition

11.2. Key Cross Competition- Potential therapies

11.3. Troriluzole: BioHaven Pharmaceuticals

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. Escitalopram: Allergan

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Safety and Efficacy

11.4.5. Product Profile

12. Market Size: Generalized Anxiety Disorder

12.1. Key Findings

12.2. Total Market Size of Generalized Anxiety Disorder in 7MM

12.3. Total Market Size of Generalized Anxiety Disorder by Therapies in 7MM

13. Market Outlook: 7 MM

14. Market Drivers

15. Market Barriers

16. Bibliography

17. Appendix

17.1. Report Methodology

18. Researcher Capabilities

19. Disclaimer

20. About the Publisher

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900